

Global Adalimumab (Humira) and Biosimilar Market Growth 2026-2032

<https://marketpublishers.com/r/G0526763E3C3EN.html>

Date: September 2026

Pages: 120

Price: US\$ 3,660.00 (Single User License)

ID: G0526763E3C3EN

Abstracts

The global Adalimumab (Humira) and Biosimilar market size is predicted to grow from US\$ 18950 million in 2025 to US\$ 13010 million in 2032; it is expected to grow at a CAGR of -5.3% from 2026 to 2032.

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.

LP Information, Inc. (LPI) ' newest research report, the "Adalimumab (Humira) and Biosimilar Industry Forecast" looks at past sales and reviews total world Adalimumab (Humira) and Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Adalimumab (Humira) and Biosimilar sales for 2026 through 2032. With Adalimumab (Humira) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Adalimumab (Humira) and Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Adalimumab

(Humira) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adalimumab (Humira) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adalimumab (Humira) and Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adalimumab (Humira) and Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adalimumab (Humira) and Biosimilar.

This report presents a comprehensive overview, market shares, and growth opportunities of Adalimumab (Humira) and Biosimilar market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Syringe

Pen

Segmentation by Application:

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn's Disease

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

AbbVie

Eisai

Cadila Healthcare

Torrent Pharmaceuticals

Amgen

Boehringer Ingelheim

Novartis

Samsung Bioepis

Viartis

Pfizer

Fresenius Kabi

Coherus

Key Questions Addressed in this Report

What is the 10-year outlook for the global Adalimumab (Humira) and Biosimilar market?

What factors are driving Adalimumab (Humira) and Biosimilar market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Adalimumab (Humira) and Biosimilar market opportunities vary by end market size?

How does Adalimumab (Humira) and Biosimilar break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Adalimumab (Humira) and Biosimilar Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Adalimumab (Humira) and Biosimilar by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Adalimumab (Humira) and Biosimilar by Country/Region, 2021, 2025 & 2032
- 2.2 Adalimumab (Humira) and Biosimilar Segment by Type
 - 2.2.1 Syringe
 - 2.2.2 Pen
 - 2.2.3 Adalimumab (Humira) and Biosimilar Sales by Type
 - 2.2.3.1 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Adalimumab (Humira) and Biosimilar Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Adalimumab (Humira) and Biosimilar Sale Price by Type (2021-2026)
- 2.3 Adalimumab (Humira) and Biosimilar Segment by Application
 - 2.3.1 Ankylosing Spondylitis
 - 2.3.2 Rheumatoid Arthritis
 - 2.3.3 Crohn's Disease
 - 2.3.4 Other
 - 2.3.5 Adalimumab (Humira) and Biosimilar Sales by Application
 - 2.3.5.1 Global Adalimumab (Humira) and Biosimilar Sale Market Share by Application (2021-2026)
 - 2.3.5.2 Global Adalimumab (Humira) and Biosimilar Revenue and Market Share by

Application (2021-2026)

2.3.5.3 Global Adalimumab (Humira) and Biosimilar Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Adalimumab (Humira) and Biosimilar Breakdown Data by Company

3.1.1 Global Adalimumab (Humira) and Biosimilar Annual Sales by Company (2021-2026)

3.1.2 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Company (2021-2026)

3.2 Global Adalimumab (Humira) and Biosimilar Annual Revenue by Company (2021-2026)

3.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Company (2021-2026)

3.2.2 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Company (2021-2026)

3.3 Global Adalimumab (Humira) and Biosimilar Sale Price by Company

3.4 Key Manufacturers Adalimumab (Humira) and Biosimilar Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Adalimumab (Humira) and Biosimilar Product Location Distribution

3.4.2 Players Adalimumab (Humira) and Biosimilar Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ADALIMUMAB (HUMIRA) AND BIOSIMILAR BY GEOGRAPHIC REGION

4.1 World Historic Adalimumab (Humira) and Biosimilar Market Size by Geographic Region (2021-2026)

4.1.1 Global Adalimumab (Humira) and Biosimilar Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Adalimumab (Humira) and Biosimilar Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Adalimumab (Humira) and Biosimilar Market Size by Country/Region (2021-2026)

4.2.1 Global Adalimumab (Humira) and Biosimilar Annual Sales by Country/Region (2021-2026)

4.2.2 Global Adalimumab (Humira) and Biosimilar Annual Revenue by Country/Region (2021-2026)

4.3 Americas Adalimumab (Humira) and Biosimilar Sales Growth

4.4 APAC Adalimumab (Humira) and Biosimilar Sales Growth

4.5 Europe Adalimumab (Humira) and Biosimilar Sales Growth

4.6 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Growth

5 AMERICAS

5.1 Americas Adalimumab (Humira) and Biosimilar Sales by Country

5.1.1 Americas Adalimumab (Humira) and Biosimilar Sales by Country (2021-2026)

5.1.2 Americas Adalimumab (Humira) and Biosimilar Revenue by Country (2021-2026)

5.2 Americas Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026)

5.3 Americas Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Adalimumab (Humira) and Biosimilar Sales by Region

6.1.1 APAC Adalimumab (Humira) and Biosimilar Sales by Region (2021-2026)

6.1.2 APAC Adalimumab (Humira) and Biosimilar Revenue by Region (2021-2026)

6.2 APAC Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026)

6.3 APAC Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Adalimumab (Humira) and Biosimilar by Country

- 7.1.1 Europe Adalimumab (Humira) and Biosimilar Sales by Country (2021-2026)
- 7.1.2 Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2021-2026)
- 7.2 Europe Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026)
- 7.3 Europe Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Adalimumab (Humira) and Biosimilar by Country
 - 8.1.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026)
- 8.3 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Adalimumab (Humira) and Biosimilar
- 10.3 Manufacturing Process Analysis of Adalimumab (Humira) and Biosimilar
- 10.4 Industry Chain Structure of Adalimumab (Humira) and Biosimilar

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Adalimumab (Humira) and Biosimilar Distributors

11.3 Adalimumab (Humira) and Biosimilar Customer

12 WORLD FORECAST REVIEW FOR ADALIMUMAB (HUMIRA) AND BIOSIMILAR BY GEOGRAPHIC REGION

12.1 Global Adalimumab (Humira) and Biosimilar Market Size Forecast by Region

12.1.1 Global Adalimumab (Humira) and Biosimilar Forecast by Region (2027-2032)

12.1.2 Global Adalimumab (Humira) and Biosimilar Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Adalimumab (Humira) and Biosimilar Forecast by Type (2027-2032)

12.7 Global Adalimumab (Humira) and Biosimilar Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 AbbVie

13.1.1 AbbVie Company Information

13.1.2 AbbVie Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

13.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 AbbVie Main Business Overview

13.1.5 AbbVie Latest Developments

13.2 Eisai

13.2.1 Eisai Company Information

13.2.2 Eisai Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

13.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Eisai Main Business Overview

- 13.2.5 Eisai Latest Developments
- 13.3 Cadila Healthcare
 - 13.3.1 Cadila Healthcare Company Information
 - 13.3.2 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Cadila Healthcare Main Business Overview
 - 13.3.5 Cadila Healthcare Latest Developments
- 13.4 Torrent Pharmaceuticals
 - 13.4.1 Torrent Pharmaceuticals Company Information
 - 13.4.2 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Torrent Pharmaceuticals Main Business Overview
 - 13.4.5 Torrent Pharmaceuticals Latest Developments
- 13.5 Amgen
 - 13.5.1 Amgen Company Information
 - 13.5.2 Amgen Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Amgen Main Business Overview
 - 13.5.5 Amgen Latest Developments
- 13.6 Boehringer Ingelheim
 - 13.6.1 Boehringer Ingelheim Company Information
 - 13.6.2 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Boehringer Ingelheim Main Business Overview
 - 13.6.5 Boehringer Ingelheim Latest Developments
- 13.7 Novartis
 - 13.7.1 Novartis Company Information
 - 13.7.2 Novartis Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.7.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.7.4 Novartis Main Business Overview
- 13.7.5 Novartis Latest Developments
- 13.8 Samsung Bioepis
 - 13.8.1 Samsung Bioepis Company Information
 - 13.8.2 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Samsung Bioepis Main Business Overview
 - 13.8.5 Samsung Bioepis Latest Developments
- 13.9 Viatris
 - 13.9.1 Viatris Company Information
 - 13.9.2 Viatris Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Viatris Main Business Overview
 - 13.9.5 Viatris Latest Developments
- 13.10 Pfizer
 - 13.10.1 Pfizer Company Information
 - 13.10.2 Pfizer Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 Pfizer Main Business Overview
 - 13.10.5 Pfizer Latest Developments
- 13.11 Fresenius Kabi
 - 13.11.1 Fresenius Kabi Company Information
 - 13.11.2 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.11.4 Fresenius Kabi Main Business Overview
 - 13.11.5 Fresenius Kabi Latest Developments
- 13.12 Coherus
 - 13.12.1 Coherus Company Information
 - 13.12.2 Coherus Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications
 - 13.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Revenue, Price and

Gross Margin (2021-2026)

13.12.4 Coherus Main Business Overview

13.12.5 Coherus Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Adalimumab (Humira) and Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Adalimumab (Humira) and Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Syringe

Table 4. Major Players of Pen

Table 5. Global Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026) & (K Units)

Table 6. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2021-2026)

Table 7. Global Adalimumab (Humira) and Biosimilar Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2021-2026)

Table 9. Global Adalimumab (Humira) and Biosimilar Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global Adalimumab (Humira) and Biosimilar Sale by Application (2021-2026) & (K Units)

Table 11. Global Adalimumab (Humira) and Biosimilar Sale Market Share by Application (2021-2026)

Table 12. Global Adalimumab (Humira) and Biosimilar Revenue by Application (2021-2026) & (\$ million)

Table 13. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2021-2026)

Table 14. Global Adalimumab (Humira) and Biosimilar Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global Adalimumab (Humira) and Biosimilar Sales by Company (2021-2026) & (K Units)

Table 16. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Company (2021-2026)

Table 17. Global Adalimumab (Humira) and Biosimilar Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Company (2021-2026)

Table 19. Global Adalimumab (Humira) and Biosimilar Sale Price by Company

(2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers Adalimumab (Humira) and Biosimilar Producing Area Distribution and Sales Area

Table 21. Players Adalimumab (Humira) and Biosimilar Products Offered

Table 22. Adalimumab (Humira) and Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Adalimumab (Humira) and Biosimilar Sales by Geographic Region (2021-2026) & (K Units)

Table 26. Global Adalimumab (Humira) and Biosimilar Sales Market Share Geographic Region (2021-2026)

Table 27. Global Adalimumab (Humira) and Biosimilar Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 28. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Geographic Region (2021-2026)

Table 29. Global Adalimumab (Humira) and Biosimilar Sales by Country/Region (2021-2026) & (K Units)

Table 30. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Country/Region (2021-2026)

Table 31. Global Adalimumab (Humira) and Biosimilar Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas Adalimumab (Humira) and Biosimilar Sales by Country (2021-2026) & (K Units)

Table 34. Americas Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2021-2026)

Table 35. Americas Adalimumab (Humira) and Biosimilar Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026) & (K Units)

Table 37. Americas Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026) & (K Units)

Table 38. APAC Adalimumab (Humira) and Biosimilar Sales by Region (2021-2026) & (K Units)

Table 39. APAC Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2021-2026)

Table 40. APAC Adalimumab (Humira) and Biosimilar Revenue by Region (2021-2026)

& (\$ millions)

Table 41. APAC Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026) & (K Units)

Table 42. APAC Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026) & (K Units)

Table 43. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2021-2026) & (K Units)

Table 44. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026) & (K Units)

Table 46. Europe Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026) & (K Units)

Table 47. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Adalimumab (Humira) and Biosimilar

Table 52. Key Market Challenges & Risks of Adalimumab (Humira) and Biosimilar

Table 53. Key Industry Trends of Adalimumab (Humira) and Biosimilar

Table 54. Adalimumab (Humira) and Biosimilar Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Adalimumab (Humira) and Biosimilar Distributors List

Table 57. Adalimumab (Humira) and Biosimilar Customer List

Table 58. Global Adalimumab (Humira) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global Adalimumab (Humira) and Biosimilar Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas Adalimumab (Humira) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas Adalimumab (Humira) and Biosimilar Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC Adalimumab (Humira) and Biosimilar Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC Adalimumab (Humira) and Biosimilar Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Adalimumab (Humira) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Adalimumab (Humira) and Biosimilar Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Adalimumab (Humira) and Biosimilar Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Adalimumab (Humira) and Biosimilar Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global Adalimumab (Humira) and Biosimilar Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Adalimumab (Humira) and Biosimilar Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. AbbVie Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 73. AbbVie Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 74. AbbVie Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. AbbVie Main Business

Table 76. AbbVie Latest Developments

Table 77. Eisai Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 78. Eisai Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 79. Eisai Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Eisai Main Business

Table 81. Eisai Latest Developments

Table 82. Cadila Healthcare Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 83. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 84. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Cadila Healthcare Main Business

Table 86. Cadila Healthcare Latest Developments

Table 87. Torrent Pharmaceuticals Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 88. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 89. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Torrent Pharmaceuticals Main Business

Table 91. Torrent Pharmaceuticals Latest Developments

Table 92. Amgen Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 93. Amgen Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 94. Amgen Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Amgen Main Business

Table 96. Amgen Latest Developments

Table 97. Boehringer Ingelheim Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 98. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 99. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Boehringer Ingelheim Main Business

Table 101. Boehringer Ingelheim Latest Developments

Table 102. Novartis Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 103. Novartis Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 104. Novartis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Novartis Main Business

Table 106. Novartis Latest Developments

Table 107. Samsung Bioepis Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 108. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 109. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. Samsung Bioepis Main Business

Table 111. Samsung Bioepis Latest Developments

Table 112. Viatris Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 113. Viatris Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 114. Viatris Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 115. Viatris Main Business

Table 116. Viatris Latest Developments

Table 117. Pfizer Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 118. Pfizer Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 119. Pfizer Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 120. Pfizer Main Business

Table 121. Pfizer Latest Developments

Table 122. Fresenius Kabi Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 123. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 124. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 125. Fresenius Kabi Main Business

Table 126. Fresenius Kabi Latest Developments

Table 127. Coherus Basic Information, Adalimumab (Humira) and Biosimilar Manufacturing Base, Sales Area and Its Competitors

Table 128. Coherus Adalimumab (Humira) and Biosimilar Product Portfolios and Specifications

Table 129. Coherus Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 130. Coherus Main Business

Table 131. Coherus Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Adalimumab (Humira) and Biosimilar
- Figure 2. Adalimumab (Humira) and Biosimilar Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Adalimumab (Humira) and Biosimilar Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Adalimumab (Humira) and Biosimilar Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Adalimumab (Humira) and Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Adalimumab (Humira) and Biosimilar Sales Market Share by Country/Region (2025)
- Figure 10. Adalimumab (Humira) and Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Syringe
- Figure 12. Product Picture of Pen
- Figure 13. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type in 2026
- Figure 14. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2021-2026)
- Figure 15. Adalimumab (Humira) and Biosimilar Consumed in Ankylosing Spondylitis
- Figure 16. Global Adalimumab (Humira) and Biosimilar Market: Ankylosing Spondylitis (2021-2026) & (K Units)
- Figure 17. Adalimumab (Humira) and Biosimilar Consumed in Rheumatoid Arthritis
- Figure 18. Global Adalimumab (Humira) and Biosimilar Market: Rheumatoid Arthritis (2021-2026) & (K Units)
- Figure 19. Adalimumab (Humira) and Biosimilar Consumed in Crohn's Disease
- Figure 20. Global Adalimumab (Humira) and Biosimilar Market: Crohn's Disease (2021-2026) & (K Units)
- Figure 21. Adalimumab (Humira) and Biosimilar Consumed in Other
- Figure 22. Global Adalimumab (Humira) and Biosimilar Market: Other (2021-2026) & (K Units)
- Figure 23. Global Adalimumab (Humira) and Biosimilar Sale Market Share by Application (2025)

Figure 24. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application in 2026

Figure 25. Adalimumab (Humira) and Biosimilar Sales by Company in 2026 (K Units)

Figure 26. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Company in 2026

Figure 27. Adalimumab (Humira) and Biosimilar Revenue by Company in 2026 (\$ millions)

Figure 28. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Company in 2026

Figure 29. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Adalimumab (Humira) and Biosimilar Sales 2021-2026 (K Units)

Figure 32. Americas Adalimumab (Humira) and Biosimilar Revenue 2021-2026 (\$ millions)

Figure 33. APAC Adalimumab (Humira) and Biosimilar Sales 2021-2026 (K Units)

Figure 34. APAC Adalimumab (Humira) and Biosimilar Revenue 2021-2026 (\$ millions)

Figure 35. Europe Adalimumab (Humira) and Biosimilar Sales 2021-2026 (K Units)

Figure 36. Europe Adalimumab (Humira) and Biosimilar Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue 2021-2026 (\$ millions)

Figure 39. Americas Adalimumab (Humira) and Biosimilar Sales Market Share by Country in 2026

Figure 40. Americas Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2021-2026)

Figure 41. Americas Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2021-2026)

Figure 42. Americas Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2021-2026)

Figure 43. United States Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Adalimumab (Humira) and Biosimilar Sales Market Share by Region in 2026

Figure 48. APAC Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2021-2026)

Figure 49. APAC Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2021-2026)

Figure 50. APAC Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2021-2026)

Figure 51. China Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Country in 2026

Figure 59. Europe Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2021-2026)

Figure 60. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2021-2026)

Figure 61. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2021-2026)

Figure 62. Germany Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 63. France Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 64. UK Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 65. Italy Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$

millions)

Figure 66. Russia Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 67. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2021-2026)

Figure 70. Egypt Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 71. South Africa Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 72. Israel Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 73. Turkey Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 74. GCC Countries Adalimumab (Humira) and Biosimilar Revenue Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Adalimumab (Humira) and Biosimilar in 2026

Figure 76. Manufacturing Process Analysis of Adalimumab (Humira) and Biosimilar

Figure 77. Industry Chain Structure of Adalimumab (Humira) and Biosimilar

Figure 78. Channels of Distribution

Figure 79. Global Adalimumab (Humira) and Biosimilar Sales Market Forecast by Region (2027-2032)

Figure 80. Global Adalimumab (Humira) and Biosimilar Revenue Market Share Forecast by Region (2027-2032)

Figure 81. Global Adalimumab (Humira) and Biosimilar Sales Market Share Forecast by Type (2027-2032)

Figure 82. Global Adalimumab (Humira) and Biosimilar Revenue Market Share Forecast by Type (2027-2032)

Figure 83. Global Adalimumab (Humira) and Biosimilar Sales Market Share Forecast by Application (2027-2032)

Figure 84. Global Adalimumab (Humira) and Biosimilar Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Adalimumab (Humira) and Biosimilar Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G0526763E3C3EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0526763E3C3EN.html>